14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
NPCE vs NMTC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NPCE carries a Unified Composite Score of 54.4/100 (HOLD) at $7.95 (91.7x Forward P/E, -9.6% operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin).
Growth vs. Quality Trade-Off: NPCE earns the overall head-to-head edge with a stronger Unified Composite Score (54.4/100 HOLD vs. NMTC 45.5/100 HOLD) and 1.17β · 135% Vol risk profile, whereas NMTC leads top-line expansion (+16.3% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: NPCE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.6); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NPCE vs NMTC Key Questions & Quantitative Answers
As of Nov 20, 2026, Neuropace, Inc. (NPCE) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NPCE carries a Unified Composite Score of 54.4/100 (HOLD) at $7.95 (91.7x Forward P/E, -9.6% operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin). Growth vs. Quality Trade-Off: NPCE earns the overall head-to-head edge with a stronger Unified Composite Score (54.4/100 HOLD vs. NMTC 45.5/100 HOLD) and 1.17β · 135% Vol risk profile, whereas NMTC leads top-line expansion (+16.3% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NPCE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.6); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NPCE leads the Growth & Scale pillar: NPCE posts -1.1% YoY revenue growth and +0.0% YoY earnings growth on $107M TTM revenue (77.8% gross margin, -9.6% operating margin), compared with NMTC at +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), NPCE cumulative revenue shifted +150.0% while NMTC shifted N/A. In operating R&D and SG&A reinvestment, NPCE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMTC.
NPCE screens cheaper on headline valuation multiples. NPCE trades at 91.7x Forward P/E, 91.7x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-11.6% FCF margin), whereas NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NPCE (-97.0% ROE) versus NMTC (-124.7% ROE) capital efficiency.
In options market volatility and institutional positioning, NPCE carries 59.9% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.17β · 135% Vol realized risk). By comparison, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.